Cytek acquired flow cytometry business with $43.1M revenue, $4.4M loss in 2022

Cytek Biosciences, Inc.

Purchase price was $46.5M less $1.6M working capital adjustments and transaction fees.
Net assets acquired: $44.1M assets, $5.7M liabilities, net $38.4M as of Dec 31, 2022.
FY2022 revenue: $43.1M (product $32.3M, service $10.8M); direct expenses $47.5M.
Abbreviated financials exclude corporate overhead, taxes, interest; not a standalone entity.
Acquired brands include Amnis, CellStream, Guava, Muse; closing occurred Feb 28, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.